Breast Cancer Diagnosis Platform Wins Edison Innovation Award 

An Israeli startup that uses artificial intelligence to diagnose cancer is a bronze winner in the Diagnostic Technologies category at the 2024 Edison Awards. 

Tel Aviv-based Ibex Medical Analytics won the award for its Galen Breast HER2 platform, which can accurately determine the expression in cancer slides of the protein responsible for the proliferation of breast cancer cells.  

The awards, which are named for US inventor Thomas Edison, recognize companies and innovations with a positive impact on the world.

“The advent of new therapies which hold great promise, and the continuously evolving knowledge of breast cancer, require its diagnosis be more precise than ever before to support oncologists in the identification of patients suited for breakthrough treatments,” said Ibex co-founder and CEO Joseph Mossel. 

“We are grateful for this recognition by the prestigious Edison Awards committee as we remain dedicated to bringing accurate, timely and personalized diagnosis to every patient. The award highlights our innovative approach in developing AI-powered tools such as Galen Breast HER2 that set the new standard in breast cancer diagnosis,” he said. 

“The judges were thrilled to honor Galen Breast HER2 as a groundbreaking category-changer this year, showcasing the power of innovation to improve our lives for the better,” said Edison Awards Executive Director Frank Bonafilia.